Abstracts tagged "DMOAD"

Abstract Number: 2250 • 2014 ACR/ARHP Annual Meeting
The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort
Jean-Pierre Pelletier¹, Camille Roubille¹, François Abram², Marc Dorais³, Philippe Delorme¹, Jean-Pierre Raynauld¹ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l’Île-Perrot, QC, Canada
Background/Purpose: In the perspective of personalized management of osteoarthritis (OA), a clinically relevant concern is the impact of meniscal extrusion on response to treatment. This study evaluated the role…
Abstract Number: 2145 • 2013 ACR/ARHP Annual Meeting
Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort
Johanne Martel-Pelletier¹, Camille Roubille¹, Jean-Pierre Raynauld¹, François Abram², Pierre Dodin³, Marc Dorais⁴, Philippe Delorme¹ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ⁴StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada
Background/Purpose: To explore, using data from participants enrolled in the progression cohort of the Osteoarthritis Initiative (OAI), the effects of conventional knee osteoarthritis (OA) pharmacological…
Abstract Number: L1 • 2012 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in Patients with Osteoarthritis Pain Refractory to NSAID Treatment Showed Statistically Significant Improvements in WOMAC Pain and in Biomarkers of Bone and Cartilage Degradation
Alan J. Kivitz¹, Shane G. Christensen², John Agaiby³, Egilius Spierings⁴, Julie Daves⁵, Roger Aitchison⁶, Stephen G. Miller⁷, Karsten Witt⁸ and Joseph Gimbel⁹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²J. Lewis Research, Inc., Salt Lake City, UT, ³Clinical Investigation Specialists, Gurnee, IL, ⁴MedVadis Research Corporation, Watertown, MA, ⁵Clinical Operations, Array Biopharma, Inc., Boulder, CO, ⁶Biostatistics & Data Management, Array Biopharma, Inc., Boulder, CO, ⁷Translational Medicine, Array Biopharma, Inc., Boulder, CO, ⁸Clinical Sciences, Array Biopharma, Inc., Boulder, CO, ⁹Arizona Research Center, Phoenix, AZ
Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disease and OA pain is a leading cause of work disability. p38 inhibition suppresses the production…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].